Search for cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers.
Sign up for hereditary cancer research updates.
Search Results: Treatment + Endometrial Cancer (6 results)
Treatment
People with stage I endometrial cancer who are having a hysterectomy
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas
Treatment
This study is for people with recurrent endometrial cancer
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.
Treatment
Treatment study for people with advanced cancers
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.
Treatment
Cancer treatment study for people with advanced solid tumors
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
103 results
Research Search Tool Sponsored By:
